NDRG2 and glioblastoma: The purpose of this study was to develop a clinically useful prognostic model for GBM patients to improve the precision of treatment decisions by comprehensively profiling DNA promoter methylation using four candidate genes (MGMT, NUPR1, NDRG2, and GLI1) in GBM patients in comparison to patients with non-neurooncological disease (NND).